Atlas Trials

Primary IgA Nephropathy

22 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Primary IgA Nephropathy

RecordFirmDate
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy (NCT04557462)Novartis Pharmaceuticals2021-09-20
Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE) (NCT04541043)Calliditas Therapeutics AB2020-11-17
A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy (NCT04291781)RemeGen Co., Ltd.2020-04-13
A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy (NCT04014335)Ionis Pharmaceuticals, Inc.2019-12-04
Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy (NCT03643965)Calliditas Therapeutics AB2018-09-05
Integrative Medicine of IgA Nephropathy (NCT02712697)Shanghai University of Traditional Chinese Medicine2016-06-01
Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy (NCT02765594)Peking Union Medical College Hospital2016-06-01
Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study (NCT02351752)LLiu2015-01-01
Tonsillectomy and Immunosuppression in Caucasian Patients With High-risk IgA-nephropathy (NCT07074951)St. Petersburg State Pavlov Medical University2013-03-10
The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease (NCT01738035)Calliditas Therapeutics AB2012-12-01

Track Primary IgA Nephropathy automatically

Every clearance here is in the API, with alerts when new ones post.